PHI increase sales in fourth quarter, as well
PHI hereby announces that net sales during the fourth and final fiscal quarter of 2017/18 amounted to 2.2 (1.2) MSEK, resulting in that the company saleswise achieves its best quarter ever for the second consecutive quarter. Net sales during the third quarter 2017/18 amounted to 1.4 (1.2) MSEK. The company’s fiscal year begin on May 1 to end on April 30. The company’s year-end report is set to be published on June 18, 2018.
“The encouraging sales development reflects, among other actions, our expanded direct selling and the recognition of HoloMonitor’s innovative functionality, fueled by a rapid increase in scientific publications based on its use”, said CEO Peter Egelberg.
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on May 4, 2018.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.